Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

Medtronic PLC MDT is well-positioned for a COVID-19 recovery and has upside to the consensus estimates for fiscal 2022, according to Morgan Stanley.

The Medtronic Analyst: David Lewis upgraded Medtronic from Equal-Weight to Overweight and raised the price target from $120 to $140.

The Medtronic Thesis: Lagging implantable devices are expected to outperform, with risks being abated by vaccines, better hospital protocols, the availability of personal protective equipment and COVID-19 testing, Lewis said in the upgrade note.

“We see a winning formula for Medtronic, with the company well aligned to our pro-recovery thesis and a material disconnect between Street numbers and the improving post-COVID trajectory,” the analyst said. 

"Net, we model 10% FY22/FY19 revenue growth, and Gross and Operating Margins flat in FY22 relative to FY19, which look conservative in light of CFO Karen Parkhill's guidance for a return to normalized underlying growth and Operating Margins in F4Q21."

Morgan Stanley sees reason to be more bullish about Medtronic's pipeline and the turnaround required "to make the company a structural outperformer," Lewis said. 

MDT Price Action: Shares of Medtronic were up 2.39% at $114.75 at last check Tuesday. 

Photo courtesy of Medtronic. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesHealth CarePrice TargetAnalyst RatingsGeneralDavid LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!